晚期肾细胞癌基因组注释风险模型:一项回顾性队列研究
本研究利用COMPARZ试验(训练队列,n=357)和RECORD-3试验(验证队列,n=258)的转移性肾细胞癌患者数据,将BAP1、PBRM1和TP53突变状态加入MSKCC风险模型构建基因组注释模型。训练队列中该模型将患者分为四个风险组,预测总生存和无进展生存的C指数较原模型提高,验证队列证实其优于原模型。
要点
- BAP1或TP53突变及PBRM1野生型与总生存预后相关。
- 基因组注释模型将患者分为四个风险组,预测总生存C指数0.637。
- 验证队列证实基因组注释模型优于原MSKCC模型。
核心结论
- BAP1、PBRM1和TP53突变状态在接受一线酪氨酸激酶抑制剂治疗的晚期或转移性肾细胞癌患者中具有独立预后价值。
- 使用包含这三个基因突变状态的基因组注释模型改善患者风险分层,值得在前瞻性试验中进一步研究,并可能作为临床试验中转移性肾细胞癌患者分层的模型。
研究设计与样本
- 回顾性队列研究,使用COMPARZ试验(训练队列,n=357)和RECORD-3试验(验证队列,n=258)中接受酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者的福尔马林固定石蜡包埋肿瘤组织和临床结局数据。
- COMPARZ试验训练队列纳入2008年8月至2011年9月期间分配至方案治疗的1110例患者中的357例(32%),RECORD-3试验验证队列纳入2009年10月至2011年6月期间471例可评估患者中的258例(55%)。
主要发现
- 训练队列中,TP53wt/BAP1mut、TP53mut/BAP1wt或TP53mut/BAP1mut vs TP53wt/BAP1wt的总生存风险比HR为1.57(95% CI 1.21-2.04;p=0.0008)。
- 训练队列中,PBRM1wt vs PBRM1mut的总生存风险比HR为1.58(95% CI 1.16-2.14;p=0.0035)。
- 训练队列中,原MSKCC模型将357例患者分为 favourable risk 87例(24%)、intermediate risk 217例(61%)、poor risk 53例(15%),基因组注释模型分为 favourable risk 36例(10%)、good risk 77例(22%)、intermediate risk 108例(30%)、poor risk 136例(38%)。
- 训练队列中,基因组注释模型预测总生存的C指数为0.637(95% CI 0.595-0.679),原模型为0.595(95% CI 0.557-0.634)。
- 训练队列中,基因组注释模型预测无进展生存的C指数为0.602(95% CI 0.560-0.643),原模型为0.567(95% CI 0.529-0.604)。
关键数值与推荐
- 训练队列中,BAP1或TP53任一突变或两者同时突变、以及PBRM1无突变,在总生存方面具有预后价值。
- 基因组注释模型对达到客观缓解患者比例的区分度良好(Cochran-Armitage单侧p=0.0014)。
临床怎么用
- 作者认为,包含BAP1、PBRM1和TP53突变状态的基因组注释模型值得在前瞻性试验中进一步研究,并可能作为临床试验中转移性肾细胞癌患者分层的模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is an established prognostic tool for metastatic renal-cell carcinoma that integrates clinical and laboratory data, but is agnostic to tumour genomics. Several mutations, including BAP1 and PBRM1, have prognostic value in renal-cell carcinoma. Using two independent clinical trial datasets of patients with metastatic renal-cell carcinoma, we aimed to study whether the addition of the mutation status for several candidate prognostic genes to the MSKCC model could improve the model's prognostic performance. METHODS: In this retrospective cohort study, we used available formalin-fixed paraffin-embedded tumour tissue and clinical outcome data from patients with metastatic renal-cell carcinoma assigned to treatment with tyrosine kinase inhibitors in the COMPARZ trial (training cohort; n=357) and RECORD-3 trial (validation cohort; n=258). Eligible patients in both trials were treatment-naive; had histologically confirmed, advanced, or metastatic renal-cell carcinoma; and a Karnofsky performance status score of at least 70. For each cohort, data from patients in all treatment groups (sunitinib and pazopanib in the training cohort, and everolimus and sunitinib in the validation cohort) were pooled for this analysis. In the training cohort, tumour tissue was used to evaluate somatic mutations by next-generation sequencing, and the association between cancer-specific outcomes (overall survival, progression-free survival, and overall response) and the mutation status of six genes of interest (BAP1, PBRM1, TP53, TERT, KDM5C, and SETD2) was tested. Only those genes with prognostic value in this setting were added to the MSKCC risk model to create a genomically annotated version. The validation cohort was used to independently test the prognostic value of the annotated model compared with the original MSKCC risk model. FINDINGS: 357 (32%) of 1110 patients assigned to protocol treatment in the COMPARZ study between August, 2008, and September, 2011, were evaluable for mutation status and clinical outcomes in the training cohort. The independent validation cohort included 258 (55%) of 471 evaluable patients, enrolled between October, 2009, and June, 2011, on the RECORD-3 study. In the training cohort, the presence of any mutation in BAP1 or TP53, or both, and absence of any mutation in PBRM1 were prognostic in terms of overall survival (TP53wt/BAP1mut, TP53mut/BAP1wt o TP53mut/BAP1mut vs TP53wt/BAP1wt hazard ratio [HR] 1·57, 95% CI 1·21-2·04; p=0·0008; PBRM1wt vs PBRMmut, HR 1·58, 1·16-2·14; p=0·0035). The mutation status for these three prognostic genes were added to the original MSKCC risk model to create a genomically annotated version. Distribution of participants in the training cohort into the three risk groups of the original MSKCC model changed from 87 (24%) of 357 patients deemed at favourable risk, 217 (61%) at intermediate risk, and 53 (15%) at poor risk, to distribution across four risk groups in the genomically annotated risk model, with 36 (10%) of 357 deemed at favourable risk, 77 (22%) at good risk, 108 (30%) at intermediate risk, and 136 (38%) at poor risk. Addition of genomic information improved model performance for predicting overall survival (C-index: original model, 0·595 [95% CI 0·557-0·634] vs new model, 0·637 [0·595-0·679]) and progression-free survival (0·567 [95% CI 0·529-0·604] vs 0·602 [0·560-0·643]) with adequate discrimination of the proportion of patients who achieved an objective response (Cochran-Armitage one-sided p=0·0014). Analyses in the validation cohort confirmed the superiority of the genomically annotated risk model over the original version. INTERPRETATION: The mutation status of BAP1, PBRM1, and TP53 has independent prognostic value in patients with advanced or metastatic renal-cell carcinoma treated with first-line tyrosine kinase inhibitors. Improved stratification of patients across risk groups by use of a genomically annotated model including the mutational status of these three genes warrants further investigation in prospective trials and could be of use as a model to stratify patients with metastatic renal-cell carcinoma in clinical trials. FUNDING: Novartis Pharmaceuticals Corporation, MSKCC Support Grant/Core Grant, and the J Randall & Kathleen L MacDonald Research Fund.
引用
- Voss MH, Reising A, Cheng Y, et al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncol. 2018. PMID: 30416077. doi:10.1016/S1470-2045(18)30648-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。